Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma

Clinical evidence demonstrating the effectiveness of systemic therapy for advanced salivary duct carcinoma (SDC) is lacking because of the disease's rarity. We assessed the efficacy and toxicity of trastuzumab plus docetaxel in patients with locally advanced and/or recurrent or metastatic human...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2019-01, Vol.37 (2), p.125-134
Hauptverfasser:	Takahashi, Hideaki, Tada, Yuichiro, Saotome, Takashi, Akazawa, Kohei, Ojiri, Hiroya, Fushimi, Chihiro, Masubuchi, Tatsuo, Matsuki, Takashi, Tani, Kaori, Osamura, Robert Y, Hirai, Hideaki, Yamada, Shuhei, Kawakita, Daisuke, Miura, Kouki, Kamata, Shin-Etsu, Nagao, Toshitaka
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!